DURECT Corporation Earnings Conference Call (Q1 2014) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other May 1 Calls
Today's Calls
Call Details
DURECT Corporation Earnings Conference Call (Q1 2014)
Scheduled to start Thu, May 1, 2014, 4:30 pm Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About DURECT Corp (NasdaqGM:DRRX)Other Calls 
DURECT Corporation, a specialty pharmaceutical company, is engaged in the development of pharmaceutical products based on its proprietary drug delivery technology platforms in the United States and internationally. It focuses on the development of various products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, metabolic disorders, cardiovascular disease, and other chronic diseases. The company’s products comprise ALZET product line that consists of osmotic pumps and accessories, which are used for experimental research in mice, rats, and other laboratory animals; and a range of standard and custom biodegradable polymers that are used as raw materials in the pharmaceutical and medical devices under the brand name of LACTEL. Its products also include REMOXY, an oral oxycodone gelatin capsule for chronic pain; POSIDUR, a formulation of bupivacaine for the treatment of post-surgical pain that has completed Phase III clinical study; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR-Sufentanil that has completed Phase II transdermal sufentanil patch, which is intended to provide delivery of sufentanil. In addition, the company’s products pipeline comprises ORADUR-based opioids, including hydrocodone and hydromorphone that are in Phase I clinical trials for the treatment of pain; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It has strategic agreements with various companies, such as Pain Therapeutics, Inc.; Pfizer Inc.; Zogenix, Inc.; Hospira, Inc.; and Nycomed Danmark ApS. The company was founded in 1998 and is headquartered in Cupertino, California.


More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.